CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
Recruiting
Phase 4
Interventional Study
ACS - Acute Coronary Syndrome
CYP2C19 Polymorphism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,200 (estimated)
- Sponsor
- Zunyi Medical College · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Clinical Criteria:
* Patients aged between 18-80 years old.
* Patients with ACS (UA/NSTEMI/STEMI) undergoing PCI.
* Patients will be treated with DAPT (P2Y12 inhibitors+aspirin) for at least 3 months.
* Patients are willing to provide a DNA sample (via blood draw…
Contacts